A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Virtual event on Tuesday, May 3rd at 10:00 AM ET An overview of unmet medical needs and therapeutic opportunities in schizophrenia and major neuropsychiatric disorders will be discussed CUPERTINO, Calif., April 26, 2022 -- Reviva Pharmaceuticals Holdings, Inc....
CUPERTINO, Calif., March 24, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
CUPERTINO, Calif., March 22, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- 5th Annual Neuroscience Innovation Forum - - BIO-Europe Spring® 2022 - CUPERTINO, Calif., March 18, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek...
- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023 - $29.7 Million in Cash as of December 31, 2021 - CUPERTINO, Calif., March 15, 2022 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH)...
- RECOVER is a Phase 3, randomized, double-blind study with registrational intent - - Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric indications - CUPERTINO, Calif., Feb. 01, 2022 -- Reviva Pharmaceuticals Holdings,...
- Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications - - Initiation of both Phase 3 trials is expected by end of January...
CUPERTINO, Calif., Dec. 20, 2021 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
- Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end - - Additional Phase 3 trial evaluating the long-term safety of brilaroxazine in adult patients with schizophrenia...
CUPERTINO, Calif., Sept. 15, 2021 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...